Group Profile

Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs. Within house-built proprietary chemical genomics-based drug discovery and early evaluation platform as its core competitiveness, "integrated  Chipscreen Biosciences has now become one of China's leading innovative drug enterprises, forming a modern biopharmaceutical group company in Shenzhen, as its headquarter, research and development center, and GMP production base, Chengdu, as a regional headquarter for research and development center and a large scale GMP production base for both drug substances and products, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for oncology, metabolic diseases, and autoimmune diseases.

Video

Management Team

Member Position
Dr. Lu Xianping Founder, Chairman and General Manager
Dr. Ning Zhiqiang Co-founder and Deputy General Manager, in charge of the clinical research and development system
Dr. Li Zhibin Deputy General Manager, in charge of the product development and production system
Li Jianxun Director and Deputy General Manager, in charge of the financial system
Hai Ou Director, Deputy General Manager, and Secretary of the Board, in charge of the Legal and Intellectual Property Department
Dr. Pan Desi Deputy General Manager, Chief Scientific Officer/Director of Research & Early Development Centers, in charge of the Research & Early Development Centers
Zhao Shumei Deputy General Manager, in charge of the Brand and Public Affairs Department
She Liangji Deputy General Manager, in charge of the Tumor Products Department
Zhang Libin Deputy General Manager, in charge of the Metabolic Disease Products Division
Wang Xinhao Head of the Department of Pharmaceutical Affairs and Drug Alert
He Ming Head of Commercial and Market Access Department
Liu Yingping Head of Quality Management Department
Liu Xin Head of Operations and Human Resources System
He Jie Head of Intellectual Property Protection
Zhang Jiawen Director of Business Development
Dr. Zeng Hong Executive Deputy Director of Research & Early Development Center (Chengdu)
Liu Xin (Acting) General Manager of Shenzhen Chipscreen Pharmaceutical
Xu Xuekui Deputy General Manager of Shenzhen Chipscreen Pharmaceutical
Peng Lili Deputy General Manager of Quality of Chengdu Chipscreen Pharmaceutical
Zhao Hongxiang Deputy General Manager of Production of Chengdu Chipscreen Pharmaceutical

Development Process

  • March: Shenzhen CHIPSCREEN BIOSCIENCES Co, Ltd. was established.
  • January: The international leading integrated drug discovery and early evaluation platform based on chemical genetics was successfully constructed.
  • July: Signed a cross-transfer agreement with the National Toxicology Research Center (NCTR) under the US FDA to develop the application software for drug toxicology genomics.
  • December: Chiglitazar, China's first original new drug for diabetes, was submitted for clinical trial application.
  • December: Chidamide, China's first original anti-tumor drug, was submitted for clinical trial application.
  • September: The patent technology licensing of Chidamide and the international clinical joint development agreement were signed with HUYA Biosciences Biotech Company.
  • March: The phase IIa clinical trial of Chiglitazar was completed.
  • March: The phase I clinical trial of Chidamide in China was completed.
  • February: Chidamide entered the phase II registered clinical trial for treatment of rare disease T-cell lymphoma.
  • January: Chidamide received an FDA approval to enter US clinical trials.
  • June: Chidamide was approved by the NMPA (formerly CFDA) for phase II and III clinical studies of non-small cell lung cancer, breast cancer and prostate cancer solid tumors.
  • April: Pingshan base obtained "drug production license".
  • May: The registered Phase II clinical trial of Chidamide for PTCL indication was completed.
  • February: Chidamide submitted a new drug certificate application for marketing license with PTCL as an indication to NMPA.
  • December: Chiauranib entered the phase I clinical trial.
  • March: Chidamide was approved by Japan's PMDA to enter Japan's phase I clinical trial.
  • April: Chengdu CHIPSCREEN Pharmaceutical Co, Ltd. was established.
  • May: Chiglitazar entered phase III of the registered clinical trial.
  • December: Chidamide was approved for listing by the NMPA.
  • January: Pingshan base passed the GMP certification.
  • February: Chidamide was launched for sale.
  • January: The innovative medicine production base project in Chengdu CHIPSCREEN Pharmaceutical Co, Ltd. officially started.
  • May: The phase I clinical trial of Chiauranib was completed.
  • September: Patient enrollment in the phase III trial of Chiglitazar was completed.
  • March: Shenzhen CHIPSCREEN Pharmaceutical Co, Ltd. was established.
  • April: Chidamide was approved by Taiwan TFDA to carry out a stage III breast cancer clinical trial in Taiwan.
  • July: Chidamide was included in the national health insurance catalog.
  • October: The innovative medicine research and development center of Chengdu CHIPSCREEN Pharmaceutical and the regional headquarters project were officially started.
  • March: Shenzhen CHIPSCREEN BIOSCIENCES Co, Ltd. was established.
  • May: The phase III trial for breast cancer of Chidamide was completed.
  • NDA was filed for Chiglitazar to NMPA.
  • Listed on the STAR Market on August 12.
  • NDA for Chiglitazar Sodium was accepted by NMPA.
  • Chidamide was approved for the treatment of breast cancer, a new indication, by NMPA.
  • Clinical trial application for the investigational new drug CS12192 was accepted by NMPA.

Strategic Cooperation

Corporate Culture

Mission

To save lives and bring health to patients, we are constantly dedicated in providing safe, effective, and affordable innovative drugs.

Values

Medicine, as a special product that matters human lives, should be based on science, rather than political, religious, and commercial benefits.

Social Responsibility

Care, Concern and Report

Care
Concern

Honor of the Company